Relaxin

Phase 3Small molecule

Novartis

Relaxin is one of 147 small molecule programs targeting Diffuse Scleroderma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

146

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse SclerodermaActive, not recruiting

Congestive Heart FailureActive, not recruiting

Systemic SclerosisActive, not recruiting

Heart FailureActive, not recruiting

Atrial FibrillationActive, not recruiting

Diffuse SclerodermaPhase 3

Active, not recruiting

Congestive Heart FailurePhase 2

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Heart FailurePhase 2/Phase 3

Active, not recruiting

Atrial FibrillationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Relaxin

Novartis

Phase 3

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Monoferric

PPharmacosmos A/S

Preclinical

5 5

Activase

Savaysa

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 8

Xifaxan

SSalix

Preclinical

2 9

Zoloft

VViatris Specialty LLC

Preclinical

2 10

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Not yet recruiting

Atrial Fibrillation

NCT07359872

Clinical

Trials by Indication[1]

Diffuse Scleroderma1 trial

Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma

Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 3·NCT00704665·231 enrolled

MODY1 trial

A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin

Unknown status·—·Phase 2·NCT03449251·170 enrolled

Heart Failure1 trial

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

Completed· Novartis logo

Novartis·Phase 2/3·NCT00520806·1,161 enrolled

Systemic Sclerosis1 trial

Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004380·1 enrolled

Atrial Fibrillation1 trial

Relaxin Therapy for Atrial Fibrillation

Not yet recruiting·DDeeptankar DeMazumder·Phase 1/2·NCT07359872·208 enrolled

1 more indication

Congestive Heart Failure1 trial

A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure

Completed· Novartis logo

Novartis·Phase 2·NCT00259116·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Relaxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Relaxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Relaxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Relaxin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Diffuse Scleroderma1 trial

MODY1 trial

Heart Failure1 trial

Systemic Sclerosis1 trial

Atrial Fibrillation1 trial

Congestive Heart Failure1 trial

References

Drug Info

Quick Facts

Related News